Portfolio
Portfolio
Harmony Biosciences (NASDAQ: HRMY) develops and commercializes innovative therapies for patients with rare neurological diseases.
Harmony Biosciences (NASDAQ: HRMY) develops and commercializes innovative therapies for patients with rare neurological diseases.
Click on chart to enlarge.
Harmony Biosciences (NASDAQ: HRMY) develops and commercializes innovative therapies for patients with rare neurological diseases.
Click on chart to enlarge.
Evozyne leverages generative AI to design novel protein therapeutics for high unmet needs.
Click on chart to enlarge.
Emalex Biosciences is in late-stage development for a new class of drug for patients with Tourette syndrome and other neurological disorders.
Click on chart to enlarge.
Evozyne leverages generative AI to design novel protein therapeutics for high unmet needs.
Click on chart to enlarge.
Emalex Biosciences is in late-stage development for a new class of drug for patients with Tourette syndrome and other neurological disorders.
Click on chart to enlarge.
Evozyne leverages generative AI to design novel protein therapeutics for high unmet needs.
Emalex Biosciences is in late-stage development for a new class of drug for patients with Tourette syndrome and other neurological disorders.
Castle Creek Biosciences is a late-clinical stage regenerative medicine company focused on severe skin and connective tissue disorders.
Click on chart to enlarge.
Castle Creek Biosciences is a late-clinical stage regenerative medicine company focused on severe skin and connective tissue disorders.
Click on chart to enlarge.
Castle Creek Biosciences is a late-clinical stage regenerative medicine company focused on severe skin and connective tissue disorders.
Click on chart to enlarge.
Click on chart to enlarge.
